Evaluation of ¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective ¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).

ABSTRACT: ¹⁷⁷Lu-PSMA-617 is an effective and novel treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates and therefore efficacy may be improved using predictive tools. This study investigated the predictive value of serial ¹⁷⁷Lu-PSMA-617 SPECT/CT (¹⁷⁷Lu SPECT) imaging in monitoring treatment response. Methods: Fifty-six men with progressive mCRPC previously treated with chemotherapy and novel androgen signaling inhibitor were enrolled into the LuPIN trial and received up to 6 doses of ¹⁷⁷Lu-PSMA-617 and a radiation sensitizer (3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol [NOX66]). ⁶⁸Ga-PSMA-11 and ¹⁸F-FDG PET/CT were performed at study entry and exit, and ¹⁷⁷Lu SPECT f

SUBMITTER: Pathmanandavel S 

PROVIDER: S-EPMC9902857 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature